©2026 Bryn Mawr Communications, LLC.
All Rights Reserved

Terms and Conditions • Privacy Policy
DURAVYU™ (vorolanib intravitreal insert)

TKIs: How Do They Work?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Show Description +

Jayanth Sridhar, MD, and Durga S. Borkar, MD, MMCi, review a potentially new therapeutic class to treat wet age-related macular degeneration and diabetic macular edema. Dr. Borkar explains how tyrosine kinase inhibitors (TKIs) represent a novel mechanism of action in the treatment of retinal disease, sharing how vorolanib, a potent TKI, inhibits all VEGF signaling at the receptor level.

Posted: 5/16/2025

Keywords:

TKI

•

tyrosine-kinase inhibitor

•

EyePoint Pharmaceuticals

•

EYP-1901

•

Age-Related Macular Degeneration (AMD)

•

Wet AMD

•

Imported Tags > DME

•

vorolanib

•

DURAVYU

•

An overview of TKIs and how they may fit into the wAMD treatment regimen

Up Next

What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?
What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

An overview of TKIs and how they may fit into the wAMD treatment regimen

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?
Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Wet AMD and DME Therapy in Development
Wet AMD and DME Therapy in Development

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

TKIs: How Do They Work?
TKIs: How Do They Work?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?
What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What Evidence Makes EYP-1901 a Potential Treatment for Wet AMD and DME?
What Evidence Makes EYP-1901 a Potential Treatment for Wet AMD and DME?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

How Can a Multi-MOA Approach Benefit the Management of Wet AMD?
How Can a Multi-MOA Approach Benefit the Management of Wet AMD?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Reinjection Criteria
Reinjection Criteria

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Patient Selection for EYP-1901
Patient Selection for EYP-1901

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Additional Videos

EYP1901 Mechanism of Action
EYP1901 Mechanism of Action

link-arrow   Back to All Videos

TKIs: How Do They Work?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Jayanth Sridhar, MD, and Durga S. Borkar, MD, MMCi, review a potentially new therapeutic class to treat wet age-related macular degeneration and diabetic macular edema. Dr. Borkar explains how tyrosine kinase inhibitors (TKIs) represent a novel mechanism of action in the treatment of retinal disease, sharing how vorolanib, a potent TKI, inhibits all VEGF signaling at the receptor level.

Posted: 5/16/2025

Keywords:

TKI

•

tyrosine-kinase inhibitor

•

EyePoint Pharmaceuticals

•

EYP-1901

•

Age-Related Macular Degeneration (AMD)

•

Wet AMD

•

Imported Tags > DME

•

vorolanib

•

DURAVYU

•

An overview of TKIs and how they may fit into the wAMD treatment regimen

Resources

Addressing the Gaps in Duration of Treatment for Age-Related Macular Degeneration

View Resource

Scientific Publications image

Scientific Publications

View Resource

Image Gallery

Duravyu MOA

About EyePoint, Inc

EYP-1901 is an investigational product and the safety and efficacy of EYP-1901 has not been established. FDA has not approved EYP-1901 in the United States. The materials discussed on this site do not predict future FDA approval. Conclusive evidence of efficacy and safety of EYP-1901 will require further investigation in well-controlled Phase 3 clinical trials

Visit us online: eyepointpharma.com

Follow EyePoint, Inc

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU™ is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

DURAVYU (EYP-1901), is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E™ - efficacy and safety have not yet been established with well controlled, phase 3 pivotal trials.